Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 51Urinary Bladder Neoplasms 15Breast Neoplasms 10Carcinoma, Renal Cell 8Colorectal Neoplasms 7Neoplasms 6Lung Neoplasms 6Pancreatic Neoplasms 5Ovarian Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Non-Small-Cell Lung 4Motor Activity 3Colonic Neoplasms 3Urologic Neoplasms 2Urologic Diseases 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Rectal Neoplasms 2Prostate Cancer Metastatic 2Neoplasms by Site 2Neoplasm Metastasis 2Melanoma 2Kidney Neoplasms 2Kidney Failure, Chronic 2Esophageal Neoplasms 2COVID-19 2Breast Neoplasms, Male 2

Interventions

Nutrition Assessment 2tocilizumab 1Tirzepatide 1Testosterone 1Standard of Care 1Specimen Handling 1Resistance Training 1Practice Guidelines as Topic 1Pioglitazone 1Palliative Care 1Metformin 1Lysine Acetyltransferase 5 1Immunoglobulin G 1Gonadotropin-Releasing Hormone 1Exercise 1Disulfides 1Diet, Carbohydrate-Restricted 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diabetes Mellitus × Standard of Care × Genitourinary × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡